The prevalence of underpowered randomized clinical trials in rheumatology

Journal of Rheumatology

Volumn 32, Issue 11, 2005, Pages 2083-2088

  Keen, Helen I ^a   Pile, Kevin ^a   Hill, Catherine L ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Randomized clinical trial; Rheumatology; Sample size calculation

Indexed keywords

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FIBROMYALGIA; GOUT; HUMAN; HUMEROSCAPULAR PERIARTHRITIS; MAJOR CLINICAL STUDY; MYOSITIS; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PSEUDOGOUT; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; REACTIVE ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SAMPLING; SJOEGREN SYNDROME; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; CLINICAL TRIALS, PHASE III; DATA INTERPRETATION, STATISTICAL; HUMANS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 27744435776     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Halpern S, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288:358-62.
2. Newell DJ. Type II errors and ethics. BMJ 1978;4:1789.
3. Altman DG. Statistics and ethics in medical research: III. How large a sample? BMJ 1980;281:1336-8.
4. Edwards SJL, Lilford RJ, Braunholtz D, Jackson J. Why "underpowered" trials are not necessarily unethical. Lancet 1997;350:804-7.
5. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomised controlled trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
6. Donner A, Eliasziw M. A goodness-of-fit approach to inference procedures for the kappa statistic: confidence interval construction, significance-testing and sample size estimation. Stat Med 1992;11:1511-9.
7. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal antiinflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
8. Bellamy N, Carette S, Ford PM, et al. Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials - results of consensus development (delphi) exercise. J Rheumatol 1992;19:451-7.
9. Chalmers TC, Lau J. Meta-analytic stimulus for changes in clinical trials. Stat Methods Med Res 1993;2:161-72.
10. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
11. Pham T, van der Heijde D, Lassere M, et al. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30:1648-54.
12. Moher D, Dulberg C, Wells G. Statistical power, sample size and their reporting in randomised clinical trials. JAMA 1994;272:122-4.
13. Dickinson K, Bunn F, Wentz R, Edwards P, Roberts I. Size and quality of randomised controlled trials in head injury: review of published studies. BMJ 2000;320:1308-11.
14. Hill CL, La Valley M, Felson DT. Secular changes in the quality of published randomised clinical trials in rheumatology. Arthritis Rheum 2002;46:779-84.
15. Bhandari M, Richards RR, Sprague S, Schemitsch EH. The quality of reporting of randomized trials in the Journal of Bone and Joint Surgery from 1988 through 2000. J Bone Joint Surg Am 2002;84:388-96.